{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:43Z","timestamp":1760298103588},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T00:00:00Z","timestamp":1249948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s11912-009-0046-y","type":"journal-article","created":{"date-parts":[[2009,8,10]],"date-time":"2009-08-10T05:01:07Z","timestamp":1249880467000},"page":"337-345","source":"Crossref","is-referenced-by-count":10,"title":["Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?"],"prefix":"10.1007","volume":"11","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,11]]},"reference":[{"key":"46_CR1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"B.J. Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408\u20132417.","journal-title":"N Engl J Med"},{"key":"46_CR2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1182\/blood.V112.11.186.186","volume":"112","author":"S.G. O\u2019Brien","year":"2008","unstructured":"O\u2019Brien SG, Guilhot F, Goldman J, et al.: International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract]. Blood 2008, 112:186.","journal-title":"Blood"},{"key":"46_CR3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"S.G. O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"46_CR4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"T.P. Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423\u20131432.","journal-title":"N Engl J Med"},{"key":"46_CR5","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","volume":"11","author":"J. Cortes","year":"2005","unstructured":"Cortes J, Talpaz M, O\u2019Brien S, et al.: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005, 11:3425\u20133432.","journal-title":"Clin Cancer Res"},{"key":"46_CR6","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H. Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, et al.: Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intentionto-treat analysis. J Clin Oncol 2008, 26:3358\u20133363.","journal-title":"J Clin Oncol"},{"key":"46_CR7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A. Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian HM, Cortes JE: Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009, 16:122\u2013131.","journal-title":"Cancer Control"},{"key":"46_CR8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","volume":"7","author":"E. Weisberg","year":"2007","unstructured":"Weisberg E, Manley PW, Cowan-Jacob SW, et al.: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007, 7:345\u2013356.","journal-title":"Nat Rev Cancer"},{"key":"46_CR9","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"R.A. Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, et al.: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022\u20134028.","journal-title":"Blood"},{"key":"46_CR10","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S. Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, et al.: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496\u20133499.","journal-title":"Blood"},{"key":"46_CR11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"B.J. Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038\u20131042.","journal-title":"N Engl J Med"},{"key":"46_CR12","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","volume":"17","author":"S. Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Harper A, et al.: Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003, 17:2401\u20132409.","journal-title":"Leukemia"},{"key":"46_CR13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","volume":"112","author":"H. Kantarjian","year":"2008","unstructured":"Kantarjian H, O\u2019Brien S, Shan J, et al.: Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 2008, 112:837\u2013845.","journal-title":"Cancer"},{"key":"46_CR14","first-page":"1557","volume":"357","author":"A. Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J: Tyrosine kinase inhibitors for chronic myelogenous leukemia. New Engl J Med 2007, 357:1557; author reply 1558.","journal-title":"New Engl J Med"},{"key":"46_CR15","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","volume":"103","author":"H. Kantarjian","year":"2004","unstructured":"Kantarjian H, Talpaz M, O\u2019Brien S, et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, 103:2873\u20132878.","journal-title":"Blood"},{"key":"46_CR16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2003-01-0025","volume":"102","author":"J. Cortes","year":"2003","unstructured":"Cortes J, Giles F, O\u2019Brien S, et al.: Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003, 102:83\u201386.","journal-title":"Blood"},{"key":"46_CR17","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"T.P. Hughes","year":"2008","unstructured":"Hughes TP, Branford S, White DL, et al.: Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy. Blood 2008, 112:3965\u20133973.","journal-title":"Blood"},{"key":"46_CR18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V112.11.335.335","volume":"112","author":"J. Cortes","year":"2008","unstructured":"Cortes J, Baccarani M, Guilhot F, et al.: A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study [abstract]. Blood 2008, 112:335.","journal-title":"Blood"},{"key":"46_CR19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.V112.11.185.185","volume":"112","author":"M. Baccarani","year":"2008","unstructured":"Baccarani M, Castagnetti F, Simonsson B, et al.: Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of an European Leukemianet prospective study comparing 400 mg and 800 mg front-line [abstract]. Blood 2008, 112:185.","journal-title":"Blood"},{"key":"46_CR20","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","volume":"113","author":"E. Jabbour","year":"2009","unstructured":"Jabbour E, Kantarjian HM, Jones D, et al.: Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113:2154\u20132160.","journal-title":"Blood"},{"key":"46_CR21","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"L.J. Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, et al.: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658\u20136661.","journal-title":"J Med Chem"},{"key":"46_CR22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"N.P. Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399\u2013401.","journal-title":"Science"},{"key":"46_CR23","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T. O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500\u20134505.","journal-title":"Cancer Res"},{"key":"46_CR24","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M. Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531\u20132541.","journal-title":"N Engl J Med"},{"issue":"May20Suppl","key":"46_CR25","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/jco.2008.26.15_suppl.7009","volume":"26","author":"M. Mauro","year":"2008","unstructured":"Mauro M, Baccarani M, Cervantes F, et al.: Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol 2008, 26(May 20 Suppl):7009.","journal-title":"J Clin Oncol"},{"issue":"May20Suppl","key":"46_CR26","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1200\/jco.2008.26.15_suppl.7012","volume":"26","author":"P. Rousselot","year":"2008","unstructured":"Rousselot P, Facon T, Paquette R, et al.: Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standarddose imatinib: 2-year follow-up data from START-R [abstract]. J Clin Oncol 2008, 26(May 20 Suppl):7012.","journal-title":"J Clin Oncol"},{"key":"46_CR27","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood.V112.11.3225.3225","volume":"112","author":"N. Shah","year":"2008","unstructured":"Shah N, Kim DW, Kantarjian H, et al.: Dasatinib doseoptimization in chronic phase chronic myeloid leukemia (CML-CP): two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose [abstract]. Blood 2008, 112:3225.","journal-title":"Blood"},{"key":"46_CR28","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood.V112.11.3224.3224","volume":"112","author":"H. Kantarjian","year":"2008","unstructured":"Kantarjian H, Kim DW, Dorlhiac-Llacer P, et al.: Dasatinib 140 mg once daily demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily in patients with accelerated phase chronic myeloid leukemia: 2-year follow-up data from CA180-035 [abstract]. Blood 2008, 112:3224.","journal-title":"Blood"},{"key":"46_CR29","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1182\/blood.V112.11.3226.3226","volume":"112","author":"G. Saglio","year":"2008","unstructured":"Saglio G, Kantarjian H, Hochhaus A, et al.: Dasatinib 140 mg once daily demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily in patients with chronic myeloid leukemia in blast phase: 2-year data from CA180-035 [abstract]. Blood 2008, 112:3226.","journal-title":"Blood"},{"key":"46_CR30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E. Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129\u2013141.","journal-title":"Cancer Cell"},{"key":"46_CR31","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H. Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542\u20132551.","journal-title":"N Engl J Med"},{"key":"46_CR32","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1182\/blood.V112.11.3238.3238","volume":"112","author":"H. Kantarjian","year":"2008","unstructured":"Kantarjian H, Giles F, Bhalla K, et al.: Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 2008, 112:3238.","journal-title":"Blood"},{"key":"46_CR33","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"H.M. Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540\u20133546.","journal-title":"Blood"},{"key":"46_CR34","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1182\/blood.V112.11.3229.3229","volume":"112","author":"P. Coutre Le","year":"2008","unstructured":"Le Coutre P, Giles F, Hochhaus A, et al.: Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 2008, 112:3229.","journal-title":"Blood"},{"key":"46_CR35","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2006-12-061283","volume":"110","author":"F. Giles","year":"2007","unstructured":"Giles F, Larson RA, Kantarjian K, et al.: Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. Blood 2007, 110:1025.","journal-title":"Blood"},{"key":"46_CR36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/leu.2008.334","volume":"23","author":"L.L. Remsing Rix","year":"2009","unstructured":"Remsing Rix LL, Rix U, Colinge J, et al.: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009, 23:477\u2013485.","journal-title":"Leukemia"},{"key":"46_CR37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S. Redaelli","year":"2009","unstructured":"Redaelli S, Piazza R, Rostagno R, et al.: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J Clin Oncol 2009, 27:469\u2013471.","journal-title":"J Clin Oncol"},{"key":"46_CR38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.V112.11.1098.1098","volume":"112","author":"J. Cortes","year":"2008","unstructured":"Cortes J, Kantarjian H, Kim DW, et al.: Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib [abstract]. Blood 2008, 112:1098.","journal-title":"Blood"},{"key":"46_CR39","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1182\/blood-2008-04-152959","volume":"112","author":"C. Gambacorti-Passerini","year":"2008","unstructured":"Gambacorti-Passerini C, Pogliani E, Baccarani M, et al.: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL [abstract]. Blood 2008, 112:1101.","journal-title":"Blood"},{"key":"46_CR40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V112.11.181.181","volume":"112","author":"G. Rosti","year":"2008","unstructured":"Rosti G, Castagnetti F, Poerio A, et al.: High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party [abstract]. Blood 2008, 112:181.","journal-title":"Blood"},{"key":"46_CR41","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V112.11.182.182","volume":"112","author":"J. Cortes","year":"2008","unstructured":"Cortes J, O\u2019Brien S, Borthakur G, et al.: Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CMLCP) [abstract]. Blood 2008, 112:182.","journal-title":"Blood"},{"key":"46_CR42","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood.V112.11.446.446","volume":"112","author":"J. Cortes","year":"2008","unstructured":"Cortes J, O\u2019Brien S, Jones D, et al.: Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood 2008, 112:446.","journal-title":"Blood"},{"key":"46_CR43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","volume":"109","author":"A. Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Jones D, et al.: Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007, 109:497\u2013499.","journal-title":"Blood"},{"key":"46_CR44","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood-2008-01-136820","volume":"112","author":"F. Giles","year":"2008","unstructured":"Giles F, Le Coutre P, Bhalla K, et al.: Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) who failed prior imatinib and dasatinib therapy: updated results of a phase 2 study [abstract]. Blood 2008, 112:3234.","journal-title":"Blood"},{"key":"46_CR45","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/blood.V112.11.2119.2119","volume":"112","author":"R.J. Garg","year":"2008","unstructured":"Garg RJ, Kantarjian H, O\u2019Brien SM, et al.: The use of 2nd generation tyrosine kinase inhibitors (TKI) after failure to 2 prior TKI: long-term follow-up [abstract]. Blood 2008, 112:2119.","journal-title":"Blood"},{"key":"46_CR46","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","volume":"90","author":"K.M. Kozopas","year":"1993","unstructured":"Kozopas KM, Yang T, Buchan HL, et al.: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A 1993, 90:3516\u20133520.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"46_CR47","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V110.11.2912.2912","volume":"110","author":"Y. Chen","year":"2007","unstructured":"Chen Y, Hu Y, Michaels S, et al.: Inhibitory effects of homoharringtonine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice [abstract]. Blood 2007, 110:2912.","journal-title":"Blood"},{"key":"46_CR48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","volume":"109","author":"A. Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Garcia-Manero G, et al.: Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007, 109:248\u2013255.","journal-title":"Cancer"},{"key":"46_CR49","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood.V112.11.3239.3239","volume":"112","author":"J. Cortes","year":"2008","unstructured":"Cortes J, Khoury HJ, Corm S, et al.: Safety and efficacy of subcutaneous (SC) omacetaxine mepesuccinate in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation\u2014results of an ongoing multicenter phase II study [abstract]. Blood 2008, 112:3239.","journal-title":"Blood"},{"key":"46_CR50","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V112.11.3232.3232","volume":"112","author":"J. Cortes","year":"2008","unstructured":"Cortes J, Paquette R, Talpaz M, et al.: Preliminary clinical activity in a phase I trial of the BCR-ABL\/IGF-1R\/Aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation [abstract]. Blood 2008, 112:3232.","journal-title":"Blood"},{"key":"46_CR51","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V110.11.1030.1030","volume":"110","author":"R. Paquette","year":"2007","unstructured":"Paquette R, Shah N, Sawyers C, et al.: PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract]. Blood 2007, 110:1030.","journal-title":"Blood"},{"key":"46_CR52","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V112.11.726.726","volume":"112","author":"T. O\u2019Hare","year":"2008","unstructured":"O\u2019Hare T, Eide CA, Adrian LT, et al.: Complete suppression of in vitro resistance by AP24534, a pan-BCR-ABL inhibitor [abstract]. Blood 2008, 112:726.","journal-title":"Blood"},{"key":"46_CR53","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2007-07-098996","volume":"112","author":"R.A. Etten Van","year":"2008","unstructured":"Van Etten RA, Chan WW, Zaleskas VM, et al.: Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]. Blood 2008, 112:576.","journal-title":"Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-009-0046-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-009-0046-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-009-0046-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T09:03:50Z","timestamp":1590051830000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-009-0046-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,11]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["46"],"URL":"https:\/\/doi.org\/10.1007\/s11912-009-0046-y","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,11]]}}}